CTCs from HER2+ metastatic breast cancer patients, purified using a slanted spiral microchannel, were revealed to be HER2- whereas the primary tumor was HER2+, suggesting that continued therapy against HER2 would not be as effective [53,54]. The gene discussed is ERBB2; the disease is neoplasm.